Kerry Logistics Network Appoints Wong Siew Loong as Chief Commercial Officer for the Group & Managing Director for South East Asia

2024-11-21 Kerry Logistics Network Limited HaiPress

HONG KONG,Nov. 21,2024 -- Kerry Logistics Network Limited ('KLN'; Stock Code 0636.HK)is pleased to announce the appointment of Wong Siew Loong as its Chief Commercial Officer for the Group and Managing Director for SouthEast Asia. The appointment is a key step in accelerating KLN's growth strategy and advancing its development plan across the globe.

With more than 25 years of experience in the global transportation and logistics sector,Siew Loong joins KLN from Kuehne+Nagel where he last served as President of the Asia Pacific region and brings extensive international experience and proven track record. Based in Singapore,Siew Loong will lead KLN's global commercial growth strategies and operational advancement efforts to unlock new opportunities and drive greater growth.

Vic Cheung,Executive Director andCEOof KLN,said,"We are delighted to welcome Siew Loong to our leadership team. His vision for commercial excellence,along with his strong understanding of market dynamics and customer needs,will be invaluable as KLN continues to innovate and deliver exceptional value to our customers across regions and markets."

Commenting on his new appointment,Wong Siew Loong said,"I am excited to be joining KLN and bringing my commercial experience and insights to contribute value to its strategic development and long-term growth. I look forward to working collaboratively with the talented team across the network to drive success."

About Kerry Logistics Network Limited (Stock Code 0636.HK)


KLN is an Asia-based,global 3PL with a highly diversified business portfolio and extensive coverage in Asia. It offers a broad range of supply chain solutions from integrated logistics,international freight forwarding (air,ocean,road,rail and multimodal) and e-commerce to industrial project logistics and infrastructure investment.

With a global presence across 60 countries and territories,KLN has established a solid foothold in half of the world's emerging markets. Its diverse infrastructure,extensive coverage in international gateways and local expertise span across the Mainland of China,India,Southeast Asia,the CIS,Middle East,LATAM and other locations.

KLN generated a revenue of over HK$47.4 billion in 2023. It is listed on the Hong Kong Stock Exchange and is a constituent of the Hang Seng Corporate Sustainability Benchmark Index.

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

Newest

1Cangxi County Holds 2026 New Year's Cultural Performance for the Public

Cangxi County Holds 2026 New Year's Cultural Performance for the Public

2The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

3The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

4Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

5Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

6Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

©copyright 2009-2020 Diet Tips Daily